However, individuals diagnosed with triple-negative (TNBC) and HER2-positive breast cancers face lower survival rates due to the absence of effective therapeutic targets and prognostic markers (Hunter et al. 2020; Waks and Winer 2019). The gene discussed is ERBB2; the disease is breast carcinoma.